(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Vera Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast VERA's revenue for 2026 to be $3,241,259,818, with the lowest VERA revenue forecast at $909,071,198, and the highest VERA revenue forecast at $9,192,037,023. On average, 12 Wall Street analysts forecast VERA's revenue for 2027 to be $17,674,085,159, with the lowest VERA revenue forecast at $9,673,687,775, and the highest VERA revenue forecast at $35,348,883,875.
In 2028, VERA is forecast to generate $39,281,294,684 in revenue, with the lowest revenue forecast at $18,880,709,488 and the highest revenue forecast at $76,350,563,690.